Next Article in Journal
COVID-19 Pandemic and Upcoming Influenza Season—Does an Expert’s Computed Tomography Assessment Differentially Identify COVID-19, Influenza and Pneumonias of Other Origin?
Next Article in Special Issue
Predictive Value of Measures of Vascular Calcification Burden and Progression for Risk of Death in Incident to Dialysis Patients
Previous Article in Journal
Analysis of Corneal Distortion after Myopic PRK
Previous Article in Special Issue
Short- and Long-Term Evaluation of Renal Function after Radical Cystectomy and Cutaneous Ureterostomy in High-Risk Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 10
Issue 1
10.3390/jcm10010083
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy

by
Michele Magnocavallo
1,
Antonio Bellasi
2,
Marco Valerio Mariani
1,
Maria Fusaro
3,
Maura Ravera
4,
Ernesto Paoletti
4,
Biagio Di Iorio
5,
Vincenzo Barbera
6,
Domenico Giovanni Della Rocca
7,
Roberto Palumbo
8,
Paolo Severino
1,
Carlo Lavalle
1 and
Luca Di Lullo
6,*
1
Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Policlinico Universitario Umberto I, Sapienza University of Rome, 00161 Rome, Italy
2
Department of Research, Innovation and Brand Reputation, ASST-Papa Giovanni XXIII, 24127 Bergamo, Italy
3
National Council of Research, Institute of Clinical Physiology, 56124 Pisa, Italy
4
Nefrologia, Dialisi e Trapianto, Policlinico San Martino, 16132 Genova, Italy
5
Department of Nephrology and Dialysis, Moscati Hospital, 83100 Avellino, Italy
6
Department of Nephrology and Dialysis, Parodi-Delfino Hospital, 00034 Colleferro, Italy
7
Texas Cardiac Arrhythmia Institute, St. David’s Medical Center, Austin, TX 78705, USA
8
Department of Nephrology and Dialysis, Sant’Eugenio Hospital, 00144 Rome, Italy
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2021, 10(1), 83; https://doi.org/10.3390/jcm10010083
Submission received: 21 November 2020 / Revised: 21 December 2020 / Accepted: 22 December 2020 / Published: 28 December 2020
(This article belongs to the Special Issue Recent Advances in Kidney and Cardiovascular Diseases)
Browse Figures
Versions Notes

Abstract

:
Atrial fibrillation (AF) and chronic kidney disease (CKD) are strictly related; several independent risk factors of AF are often frequent in CKD patients. AF prevalence is very common among these patients, ranging between 15% and 20% in advanced stages of CKD. Moreover, the results of several studies showed that AF patients with end stage renal disease (ESRD) have a higher mortality rate than patients with preserved renal function due to an increased incidence of stroke and an unpredicted elevated hemorrhagic risk. Direct oral anticoagulants (DOACs) are currently contraindicated in patients with ESRD and vitamin K antagonists (VKAs), remaining the only drugs allowed, although they show numerous critical issues such as a narrow therapeutic window, increased tissue calcification and an unfavorable risk/benefit ratio with low stroke prevention effect and augmented risk of major bleeding. The purpose of this review is to shed light on the applications of DOAC therapy in CKD patients, especially in ESRD patients.

Graphical Abstract

1. Introduction

The prevalence of atrial fibrillation (AF) in the general population ranges between 0.5% and 1%, with peaks of 8% in patients over 80 years of age [1]. AF patients are at increased risk of thromboembolic complications, and oral anticoagulant therapy is universally recommended in clinical guidelines [2,3,4,5,6,7]. Chronic kidney disease (CKD) is also associated with increased cardiovascular disease risk and all-cause mortality [8,9,10] and is highly prevalent in the AF population, affecting 40–50% of patients with AF (Figure 1) [11,12,13].
Similarly, AF coexists in up to 15–20% of CKD subjects, especially in end stage renal disease (ESRD) patients, who are identified on the basis of an estimated glomerular filtration rate (eGFR) < 15 mL/min, including those requiring dialysis (Table 1) [2,13,14,15,16].
Furthermore, patients with advanced CKD (eGFR < 30 mL/min) are at increased risk of bleeding from uremia-induced platelet dysfunction and invasive procedures related to dialysis [17,18,19].
Randomized controlled trials demonstrated that direct oral anticoagulants (DOACs) are not inferior to warfarin for stroke or systemic embolism; however, these studies excluded patients on dialysis, those with an eGFR < 25–30 mL/min and those treated with vitamin K antagonists (VKA) other than warfarin [20,21,22,23,24,25]. Consequently, all data concerning use of DOACs in patients with eGFR < 30 mL/min came from observational studies, and the evidence in favor of DOACs in patients with advanced or ESRD is still very limited [26,27,28,29,30,31]. The aim of this review is to evaluate how treatment with DOACs affects stroke and bleeding outcomes compared with warfarin in a CKD population. Moreover, particular consideration is given to the role of long-term oral anticoagulant therapy in renal preservation function.

2. Pathophysiology of High Thromboembolic/Hemorrhagic Risk in CKD Patients

AF and CKD are strictly related and share several risk factors (hypertension, diabetes, obesity, metabolic syndrome). Consequently, the growing incidence and prevalence of AF are linked with a parallel rise in CKD and vice versa [32,33]. Furthermore, progressive worsening of kidney function is associated with an increased rate of AF, and in dialysis patients, prevalence of AF reaches about 16% [12,16,34]. Contemporary presence of AF and CKD outlines a clinical condition characterized by a very high thromboembolic risk (cardioembolic stroke, systemic thromboembolic and death) and unexpected elevated hemorrhagic risk, especially in dialysis patients.
The central role of CKD in raised thromboembolic risk is well known. Piccini et al. have demonstrated that impaired renal function is a great predictor of cardioembolic stroke and systemic embolism [35]. Therefore, for a better evaluation of thromboembolic risk, they have proposed to extend the CHADS2 score with an additional 2 points for patients with eGFR < 60 mL/min, the so-called R2CHADS2 score [35].
Several factors increase the propensity of thrombus formation in patients with CKD; as depicted in Figure 2, all Virchow’s triad elements (abnormalities in blood flow, vessel wall and blood constituents) appear abnormal. Additionally, reduced eGFR is an independent predictor of low left atrial appendage contractility and emptying velocity [36,37]. These elements promote the formation in the left atrium of dense spontaneous echocardiographic contrast, which is an indicator of relevant blood stasis and is associated with augmented thrombogenic risk [38,39].
On the other hand, CKD patients have an increased atherosclerosis susceptibility with a bigger pulse wave velocity and reduced flow-mediated endothelium-dependent dilation [40,41]. Higher endogenous levels of Endotelin-1 and plasma cAMP in CKD individuals seem to be associated with an increased thromboembolic susceptibility [42].
Lastly, CKD is associated with an increase of inflammatory and procoagulant biomarkers that enhance platelet activity and clot formation [43,44]. Reduced metabolism of C-reactive protein, anomalous expression of glycoprotein Ib, increased levels of pro-inflammatory proteins (IL-1, TNF alfa, D-Dimer) and procoagulant factors (VII, VIII, fibrinogen, Von Willebrand, plasminogen activator inhibitor-1) and inhibition of plasmin by increased levels of lipoprotein(a) are the most important hematological abnormalities described in CKD patients [45,46,47,48].
Such factors are also involved in an augmented hemorrhagic risk. Specifically, platelet abnormalities, uremic toxins, uncontrolled hypertension, repeated cannulations for dialysis and invasive procedures contribute to a remarkably high risk of bleeding (Figure 3). Above all, platelet disfunctions seem to be predominant and include reduction in intracellular ADP, impaired release of the platelet alpha-granule protein, enhanced intracellular cAMP, anomalous arachidonic acid metabolism and cyclo-oxygenase activity, aberration of the activity of GP IIb/IIIa and altered von Willebrand factor promoting a pro-hemorrhagic state [49,50,51]. Moreover, uremic toxins alter blood flow and enhance erythropoietin deficiency [51,52].
Based on previous evidence that proved the high thromboembolic/hemorrhagic risk in CKD patients, it is conceivable that a new risk chart, specifically constructed for renal patients, may improve risk stratification of both thromboembolic and hemorrhagic events [53].

3. Anticoagulant-Related Nephropathy and Progression of Kidney Disease

Despite increasing use of oral anticoagulants in the last 20 years, only in 2009 did Brodsky et al. introduce the concept of “warfarin-related nephropathy” (WRN). WRN is a particular form of acute kidney injury (AKI) without any obvious underlying cause, in a patient treated with warfarin with an international normalized ratio (INR) > 3.0 and microscopic or gross hematuria [54]. Brodsky et al. performed renal biopsies in nine patients with unexplained AKI and supratherapeutic INR; histological specimens showed a pattern of diffuse dysmorphic erythrocyte accumulation both in kidney tubules, some of which appeared obstructed and dilated, and in the glomerulus, especially in Bowman’s space [54]. The two main pathophysiological processes to explain AKI are the disruption of the glomerular filtration barrier causing bleeding into Bowman’s space and the aggregation of red blood cells, forming casts in the tubules, which lead to their obstruction and ischemia [54]. Supratherapeutic anticoagulation seems to play an essential role in inducing WRN, but it is likely that a second factor is required; a considerably reduced number of nephrons or acute damage to glomeruli seems to be the conditions contributing to glomerular bleeding in case of over-anticoagulation. Causes of acute nephron damage could be congestive heart failure, recent initiation of renin–angiotensin system inhibitors, thromboembolic kidney disease, endocapillary proliferative or crescentic glomerulonephritis or bladder clots causing ureteral obstruction. In a patient–control study enrolling 15,258 patients who initiated warfarin during a 5-year period, a presumptive diagnosis of WRN occurred in 20.5% of the entire cohort and in 33.0% of the CKD cohort [55]. The 1-year mortality in patients experiencing WRN was 31.1% compared with 18.9% in patients without WRN, which represents an increased risk of 65% [55]. Overall, WRN may be considered not only a common complication of VKA therapy but also a powerful negative prognostic factor.
Since 2009, several studies have confirmed the hypothesis proposed by Brodsky that excessive anticoagulation is associated with WRN [56,57,58,59]. Golbin et al. described the largest biopsy-proven case series of AKI induced by other VKAs, specifically the first cases of AKI by fluindione and acenocoumarol [60]. Of note, no clinical or histological differences were reported in patients treated with warfarin or fluindione/acenocoumarol [60].
The connection between AKI and anticoagulation has also been extended to DOACs; therefore, the term WRN was gradually replaced by the more inclusive “anticoagulant-related nephropathy” (ARN) [61,62,63,64]. Given the paucity of renal outcomes reported in studies involving DOACs and the lack of limited long-term data, it is possible that the true incidence of ARN is under-recognized. Two large retrospective studies demonstrated that apixaban, dabigatran and rivaroxaban are associated with a lower risk of AKI compared to warfarin (Figure 4) [26,65]. Overall, VKA administration is still considered a major risk factor for AKI, as a result of vascular calcification due to inhibition of the vitamin-K-dependent matrix gamma-carboxyglutamate protein (MGP), as depicted in Figure 5 [66,67,68,69,70]. Similar findings were also reported in a cohort of AF patients undergoing percutaneous coronary intervention; after administration of contrast medium, patients taking DOACs, especially dabigatran, showed a better control of renal function than patients on warfarin with a trend toward a reduction in the incidence of AKI [71].
Although the new European Society of Cardiology guidelines for AF recommend the use of DOACs for long-term oral anticoagulation, and the previous observational studies have showed how these drugs should play an important role in the preservation of renal function, a large study comparing DOACs across different stages of kidney function revealed that the proportion of patients using DOACs decreases in parallel to the decreasing kidney function [72]. Indeed, in patients with eGFR ≥ 90 mL/min, a DOAC was prescribed in 73.5% of cases, while in patients with eGFR between 15 and 30 mL/min, a DOAC was prescribed in only 45.0% of cases [72]. Notably, no difference in terms of mortality was reported among the three DOACs, and each one consistently showed at least equivalent effectiveness and safety compared with warfarin across the range of kidney functional stages, confirming the promising findings in this particular patient setting [72].
In conclusion, progression of kidney failure represents a central issue in the management of long-term oral anticoagulation, especially in elderly patients in which AF and CKD coexist in up to 25% of cases [13,34]. AF can deteriorate renal function over time, and eGFR worsening is an independent predictor of ischemic stroke/systemic embolism [73,74,75]. In these high thromboembolic and hemorrhagic risk patients, renal function should be regularly monitored, preferably after 1 month initially and at least every 3 months thereafter [3].

4. DOACs, Diabetes and Chronic Kidney Disease

With regard to the progression of CKD, it is crucial to highlight the close relationship between AF, diabetes mellitus (DM) and CKD; nearly 25% of patients with CKD are also diabetic [76]. As described in Figure 6, microvascular complications in DM could worsen kidney function and contribute to the onset of diabetic kidney disease (DKD), which affects about one-third of DM patients [77,78,79,80]. Long-term thromboembolic preventive therapy in AF patients with DM and CKD may be more challenging because both DM and CKD have been independently associated with an increased thromboembolic and bleeding risk, which results from the prothrombotic and pro-inflammatory status [81,82,83,84,85]. In diabetic patients, metabolic abnormalities predispose arteries to atherosclerosis and increase platelet reactivity and blood coagulability [80,81,82,86,87]. Simultaneously, progressive worsening of kidney function is associated with an increased rate of AF and a major bleeding risk [17,34].
Emerging data suggest that DOACs may be associated with better preservation of renal function when compared to warfarin [55,59,88,89]. As previously described, VKAs may also induce renal damage due to increased vascular calcification resulting from vitamin-K-dependent MGP inhibition [66,67,69]. In a study by Fusaro et al., MGP seemed to be reduced in patients affected by DM and CKD, predisposing them to a worse renal outcome when treated with VKA [90,91,92,93,94]. In contrast, rivaroxaban may provide renal preservation by decreasing vascular inflammation through reducing PAR-1 and PAR-2 signaling [95]. AF diabetic patients treated with rivaroxaban showed a lower incidence rate of hospitalization for AKI, progression to stage 5 CKD or hemodialysis than patients treated with warfarin [95]. Furthermore, in the post-hoc ROCKET AF analysis, rivaroxaban showed consistently better safety and efficacy compared to warfarin in AF patients with DM [96].
Real-world evidence supports the findings that renal function is better maintained in DM patients receiving DOACs rather than warfarin. A subgroup analysis of the RELOAD study investigated the effectiveness and safety of rivaroxaban versus warfarin in patients with AF and DM; risk of AKI and ESRD were decreased in diabetics taking rivaroxaban [95].
In an analysis performed by Yao W et al. on a large heterogeneous cohort of AF patients with diabetes (Figure 7), treatment with DOACs was related to lower incidence of worsening renal function, defined as a ≥30% decline in eGFR, doubling of serum creatinine or AKI [26].
According to the latest evidence, we consider DOACs more effective and safer than warfarin for prevention and progression of kidney disease in AF patients with diabetes.

5. DOACs and End Stage Renal Disease

The increased hemorrhagic risk and the lack of safe evidence for an effective risk/benefit ratio are the principal reasons for the restricted use of anticoagulants in CKD patients, especially those undergoing renal replacement therapy (RRT) [97]. In RRT patients, considering that the elimination of drugs is strictly dependent on the size of the molecules, the percentages linked to plasma proteins and the physicochemical properties of the dialysis filter, warfarin and DOACs are both poorly eliminated by dialysis clearance. While the superiority of DOACs vs. warfarin is well documented in patients with preserved renal function or moderate CKD, there is a lack of currently available data for DOACs in patients with severe CKD or ESRD that may lead to an increased risk of bleeding [25]. Indeed, there are no randomized controlled trial data on the use of DOACs for stroke prevention in AF patients with severe CKD or on RRT, since all landmark DOAC trials excluded patients with eGFR < 30 mL/min (except for a few patients on apixaban with eGFR 25–30 mL/min) [20,21,22,23,24].
The main data on the use of DOACs in RRT patients are from studies in the USA. Dabigatran 110 or 150 mg twice daily resulted in a higher exposure compared with standard RE-LY patients (1.5- to 3.3-fold increase in area under the curve); dabigatran 75 or 110 mg once daily produced exposures comparable to those simulated in typical RE-LY patients. These data appear to suggest that the reduced dose regimen may be more suitable for hemodialysis patients [23,98]. More detailed information is available about Apixaban’s pharmacokinetic characteristics. ESRD resulted in a modest increase (36%) in apixaban area under the curve with no increase in its peak concentration [99]. Apixaban 2.5 mg b/die administered to hemodialysis patients resulted in a drug exposure similar to that of the standard dose (5 mg b/die) in patients with preserved renal function, while apixaban 5 mg twice daily is associated with supratherapeutic levels in ESRD [100]. Moreover, apixaban is highly protein bound, and in case of a bleeding event, reversal of the anticoagulant activity with prothrombin complex concentrate should be attempted instead of dialysis.
Similar findings were reported with rivaroxaban 10 mg/die in hemodialysis patients as compared to the standard dose (20 mg/die) in patients with normal kidney function [101]. Surprisingly, deterioration of renal function from severe to ESRD does not seem to have a significant impact on the rivaroxaban pharmacokinetic and anticoagulation effect compared with those changes observed with either moderate or severe renal impairment [102].
Although current data on the efficacy and safety of DOACs in ESRD are limited, they are very encouraging (Figure 8) [103].
In a retrospective cohort study, apixaban was superior in ESRD patients in terms of both safety and effectiveness when compared with warfarin; both the standard (5 mg/bd) and the reduced (2.5 mg/bd) doses of apixaban were associated with lower major bleeding risks, but only the standard dose was associated with reduced thromboembolic events and mortality [30]. Miao B et al. compared rivaroxaban and apixaban in ESRD patients. No significant differences were reported in terms of thromboembolic and hemorrhagic risk [31]; however, when compared to warfarin, rivaroxaban appears to be associated with a reduction of major bleeding [104]. Furthermore, a meta-analysis enrolling 71,877 patients on long-term dialysis and with AF showed that patients receiving apixaban 5 mg twice daily had a significantly lower risk of mortality than those receiving apixaban 2.5 mg twice daily, warfarin or no anticoagulant and lower bleeding risk than those on warfarin, dabigatran or rivaroxaban [105]. Overall, among patients with advanced CKD and ESRD, the use of apixaban was associated with lower risk of major bleeding compared to warfarin and was effective in preventing systemic embolism [106].
To date, only rivaroxaban 15 mg/die and apixaban 5 mg/bd (reduced dose 2.5 mg/bd in patients 80 years or older weighing 60 kg or less) are approved by the Food and Drug Administration as a long-term oral anticoagulant in ESRD patients. Despite the mounting evidence about the possibility of using DOACs in patients with eGFR < 15 mL/min, the nephrological guidelines KDIGO (Kidney Disease: Improving Global Outcomes) still recommend warfarin as the first choice drug and suggest the possibility of percutaneous or surgical closure of the left atrial appendage [107]. A randomized trial comparing DOACs and warfarin in ESRD patients might be appropriate for clarifying which is the safest and most efficient long term stroke prevention therapy in ESRD and AF patients. Randomized controlled trials are underway comparing DOACs with warfarin in advanced CKD or dialysis patients. The AXADIA study (Compare Apixaban and Vitamin-K Antagonists in Patients with Atrial Fibrillation and End-Stage Kidney Disease) is randomizing patients to apixaban 2.5 mg/bd or phenprocoumon individually adjusted to an INR of 2.0–3.0; the study completion date is scheduled for July 2023 (NCT02933697) [108]. Similar rates of major and clinically relevant non-major bleeding events were reported in the RENAL-AF trial in which patients were randomized to apixaban 5 mg/bd or warfarin (NCT02942407). Unfortunately, the study was stopped early and enrolled only 154 of the 762 expected patients, so the small sample size and low event rate are significant limitations of the study.

6. Non-Anticoagulative Approaches

Patients with ESRD represent the most complex population for long-life anticoagulant management. In the current European Guidelines, DOACs are contraindicated in patients with eGFR < 15 mL/min (ESRD), and VKAs remain the only drugs allowed [3]. Phenprocoumon and acenocoumarol have more advantageous pharmacokinetic properties than warfarin. Acenocoumarol has a shorter half-life, while the effects of CYP2C9 polymorphisms are least pronounced in the case of phenprocoumon [109,110]. On the other hand, warfarin has a narrow therapeutic window and several drug–drug and drug–food interactions; moreover, it seems to increase tissue calcification, including cardiac valves, and precipitate calcific uremic arteriolopathy [111,112,113]. For these reasons, patients treated with phenprocoumon and acenocoumarol require fewer monitoring visits than those prescribed warfarin. Nevertheless, the therapeutic range for all VKA drugs is usually unsatisfactory; as a consequence, thromboembolic and hemorrhagic events are more frequent in patients treated with VKAs than DOACs [112,114,115,116,117]. Lastly, although treatment adherence was comparable between DOACs and VKAs, treatment satisfaction and persistence are significantly lower with VKAs than DOACs; CKD and history of bleeding represent some of the main factors associated with absence and/or non-adherence to anticoagulant therapy in everyday practice [97,118,119,120].
Percutaneous left atrial appendage occlusion (LAAO) has emerged as a potential alternative to life-long oral anticoagulation because 90% or more of thrombi during AF are located in the left atrial appendage, a remnant of the primordial left atrium [121]. This strategy is currently limited to patients with a high thromboembolic and bleeding risk who are ineligible for long term OACs. Based on the available data, the use of LAAO will likely grow tremendously in the next few years because the periprocedural major adverse event rate is very low in patients with several comorbidities and high thromboembolic/hemorrhagic risk [122,123,124,125,126,127,128,129].
In patients with advanced CKD, percutaneous LAAO appears to have a similar risk of periprocedural complications compared to patients without significant renal impairment [130,131].
Additionally, recent studies have explored its efficacy for thromboembolic prevention in patients with end-stage renal disease [131,132,133,134,135]. Although not yet confirmed in large studies, these preliminary findings are highly promising. We believe that LAAO might be a valuable alternative to lifelong anticoagulation in advanced CKD patients with AF, thereby providing an effective thromboembolic prevention without increasing the risk of life-threatening bleeding events. The main drawback of endocardial LAAO is the risk of possible thrombus formation on the occlusion device. Several antithrombotic strategies have been empirically adopted in clinical practice to avoid this worrisome complication [126,127,136,137]. To date, the most common approach is based on the use of aspirin, initially with clopidogrel and then alone, to prevent activation of platelets coming in contact with the atrial surface of the device until complete endothelialization is achieved [131,132,133,134,135]. Randomized clinical trials are needed to identify the best antithrombotic therapy to prevent device-related thrombosis and explore the efficacy of LAAO in high-risk populations with a reduced safety margin between stroke prevention and bleeding risk (e.g., end-stage CKD, elderly).

7. Conclusions

Patients with CKD, especially with ESRD already in RRT, represent a challenging population for the choice of long-term anticoagulant therapy; however, mounting evidence suggests that DOACs might be a better alternative than warfarin as a result of the lower incidence of AKI and WRN and a better risk/benefit ratio.

Author Contributions

M.V.M., A.B. and M.F. have contributed for anticoagulant—related nephropathy. B.D.I., V.B., E.P. and R.P. have especially contributed to section on ESRD. M.R., P.S., C.L. and D.G.D.R. have contributed to pathophysiology’s section. M.M. and L.D.L. have provided an overview on whole articles providing to graphics, english text and assembly work. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Disclosures

All authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

ACEiAngiotensin converting enzyme inhibitor
AFAtrial fibrillation
AKIAcute kidney injury
ARNAnticoagulant-related nephropathy
CKDChronic kidney disease
DMDiabetes mellitus
DKDDiabetic kidney disease
DOACDirect oral anticoagulant
eGFREstimated glomerular filtration rate
ESRDEnd stage renal disease
INRInternational normalized ratio
LAAOLeft atrial appendage occlusion
MGPMatrix gamma-carboxyglutamate protein
RRTRenal replacement therapy
VKAVitamin K antagonist
WRNWarfarin-related nephropathy

References

  1. Kannel, W.B.; Wolf, P.A.; Benjamin, E.J.; Levy, D. Prevalence, Incidence, Prognosis, and Predisposing Conditions for Atrial Fibrillation: Population-Based Estimates 11Reprints Are Not Available. Am. J. Cardiol. 1998, 82, 2N–9N. [Google Scholar] [CrossRef]
  2. Hindricks, G.; Potpara, T.; Dagres, N.; Arbelo, E.; Bax, J.J.; Blomström-Lundqvist, C.; Boriani, G.; Castella, M.; Dan, G.-A.; Dilaveris, P.E.; et al. 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2020, ehaa612. [Google Scholar] [CrossRef] [PubMed]
  3. Steffel, J.; Verhamme, P.; Potpara, T.S.; Albaladejo, P.; Antz, M.; Desteghe, L.; Haeusler, K.G.; Oldgren, J.; Reinecke, H.; Roldan-Schilling, V.; et al. The 2018 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Eur. Heart J. 2018, 39, 1330–1393. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Turakhia, M.P.; Blankestijn, P.J.; Carrero, J.-J.; Clase, C.M.; Deo, R.; Herzog, C.A.; Kasner, S.E.; Passman, R.S.; Pecoits-Filho, R.; Reinecke, H.; et al. Chronic Kidney Disease and Arrhythmias: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur. Heart J. 2018, 39, 2314–2325. [Google Scholar] [CrossRef] [PubMed]
  5. Lip, G.Y.H.; Banerjee, A.; Boriani, G.; Chiang, C.; Fargo, R.; Freedman, B.; Lane, D.A.; Ruff, C.T.; Turakhia, M.; Werring, D.; et al. Antithrombotic Therapy for Atrial Fibrillation. Chest 2018, 154, 1121–1201. [Google Scholar] [CrossRef] [Green Version]
  6. Della Rocca, D.G.; Tarantino, N.; Trivedi, C.; Mohanty, S.; Anannab, A.; Salwan, A.S.; Gianni, C.; Bassiouny, M.; Al-Ahmad, A.; Romero, J.; et al. Non-pulmonary Vein Triggers in Nonparoxysmal Atrial Fibrillation: Implications of Pathophysiology for Catheter Ablation. J. Cardiovasc. Electrophysiol. 2020, 31, 2154–2167. [Google Scholar] [CrossRef]
  7. January, C.T.; Wann, L.S.; Calkins, H.; Chen, L.Y.; Cigarroa, J.E.; Cleveland, J.C.; Ellinor, P.T.; Ezekowitz, M.D.; Field, M.E.; Furie, K.L.; et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019, 140. [Google Scholar] [CrossRef]
  8. Kumar, S. Why Do Young People with Chronic Kidney Disease Die Early? World J. Nephrol. 2014, 3, 143. [Google Scholar] [CrossRef]
  9. Tonelli, M.; Muntner, P.; Lloyd, A.; Manns, B.J.; Klarenbach, S.; Pannu, N.; James, M.T.; Hemmelgarn, B.R. Risk of Coronary Events in People with Chronic Kidney Disease Compared with Those with Diabetes: A Population-Level Cohort Study. Lancet 2012, 380, 807–814. [Google Scholar] [CrossRef]
  10. Go, A.S.; Chertow, G.M.; Fan, D.; McCulloch, C.E.; Hsu, C. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. N. Engl. J. Med. 2004, 351, 1296–1305. [Google Scholar] [CrossRef]
  11. Ananthapanyasut, W.; Napan, S.; Rudolph, E.H.; Harindhanavudhi, T.; Ayash, H.; Guglielmi, K.E.; Lerma, E.V. Prevalence of Atrial Fibrillation and Its Predictors in Nondialysis Patients with Chronic Kidney Disease. Clin. J. Am. Soc. Nephrol. 2010, 5, 173–181. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Soliman, E.Z.; Prineas, R.J.; Go, A.S.; Xie, D.; Lash, J.P.; Rahman, M.; Ojo, A.; Teal, V.L.; Jensvold, N.G.; Robinson, N.L.; et al. Chronic Kidney Disease and Prevalent Atrial Fibrillation: The Chronic Renal Insufficiency Cohort (CRIC). Am. Heart J. 2010, 159, 1102–1107. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Hart, R.G.; Eikelboom, J.W.; Brimble, K.S.; McMurtry, M.S.; Ingram, A.J. Stroke Prevention in Atrial Fibrillation Patients with Chronic Kidney Disease. Can. J. Cardiol. 2013, 29, S71–S78. [Google Scholar] [CrossRef]
  14. Levey, A.S.; Eckardt, K.-U.; Tsukamoto, Y.; Levin, A.; Coresh, J.; Rossert, J.; De Zeeuw, D.; Hostetter, T.H.; Lameire, N.; Eknoyan, G. Definition and Classification of Chronic Kidney Disease: A Position Statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005, 67, 2089–2100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Vazquez, E.; Sanchez-Perales, C.; Garcia-Garcia, F.; Castellano, P.; Garcia-Cortes, M.-J.; Liebana, A.; Lozano, C. Atrial Fibrillation in Incident Dialysis Patients. Kidney Int. 2009, 76, 324–330. [Google Scholar] [CrossRef] [Green Version]
  16. Genovesi, S.; Pogliani, D.; Faini, A.; Valsecchi, M.G.; Riva, A.; Stefani, F.; Acquistapace, I.; Stella, A.; Bonforte, G.; DeVecchi, A.; et al. Prevalence of Atrial Fibrillation and Associated Factors in a Population of Long-Term Hemodialysis Patients. Am. J. Kidney Dis. 2005, 46, 897–902. [Google Scholar] [CrossRef]
  17. Shimizu, Y.; Maeda, K.; Imano, H.; Ohira, T.; Kitamura, A.; Kiyama, M.; Okada, T.; Ishikawa, Y.; Shimamoto, T.; Yamagishi, K.; et al. Chronic Kidney Disease and Drinking Status in Relation to Risks of Stroke and Its Subtypes: The Circulatory Risk in Communities Study (CIRCS). Stroke 2011, 42, 2531–2537. [Google Scholar] [CrossRef] [Green Version]
  18. Bos, M.J.; Koudstaal, P.J.; Hofman, A.; Breteler, M.M.B. Decreased Glomerular Filtration Rate Is a Risk Factor for Hemorrhagic But Not for Ischemic Stroke: The Rotterdam Study. Stroke 2007, 38, 3127–3132. [Google Scholar] [CrossRef] [Green Version]
  19. Iseki, K.; Kinjo, K.; Kimura, Y.; Osawa, A.; Fukiyama, K. Evidence for High Risk of Cerebral Hemorrhage in Chronic Dialysis Patients. Kidney Int. 1993, 44, 1086–1090. [Google Scholar] [CrossRef] [Green Version]
  20. Patel, M.R.; Mahaffey, K.W.; Garg, J.; Pan, G.; Singer, D.E.; Hacke, W.; Breithardt, G.; Halperin, J.L.; Hankey, G.J.; Piccini, J.P.; et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N. Engl. J. Med. 2011, 365, 883–891. [Google Scholar] [CrossRef] [Green Version]
  21. Giugliano, R.P.; Ruff, C.T.; Braunwald, E.; Murphy, S.A.; Wiviott, S.D.; Halperin, J.L.; Waldo, A.L.; Ezekowitz, M.D.; Weitz, J.I.; Špinar, J.; et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N. Engl. J. Med. 2013, 369, 2093–2104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Granger, C.B.; Alexander, J.H.; McMurray, J.J.V.; Lopes, R.D.; Hylek, E.M.; Hanna, M.; Al-Khalidi, H.R.; Ansell, J.; Atar, D.; Avezum, A.; et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N. Engl. J. Med. 2011, 365, 981–992. [Google Scholar] [CrossRef] [PubMed]
  23. Connolly, S.J.; Ezekowitz, M.D.; Yusuf, S.; Eikelboom, J.; Oldgren, J.; Parekh, A.; Pogue, J.; Reilly, P.A.; Themeles, E.; Varrone, J.; et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N. Engl. J. Med. 2009, 361, 1139–1151. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Coppens, M.; Synhorst, D.; Eikelboom, J.W.; Yusuf, S.; Shestakovska, O.; Connolly, S.J. Efficacy and Safety of Apixaban Compared with Aspirin in Patients Who Previously Tried but Failed Treatment with Vitamin K Antagonists: Results from the AVERROES Trial. Eur. Heart J. 2014, 35, 1856–1863. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Ruff, C.T.; Giugliano, R.P.; Braunwald, E.; Hoffman, E.B.; Deenadayalu, N.; Ezekowitz, M.D.; Camm, A.J.; Weitz, J.I.; Lewis, B.S.; Parkhomenko, A.; et al. Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials. Lancet 2014, 383, 955–962. [Google Scholar] [CrossRef]
  26. Yao, X.; Tangri, N.; Gersh, B.J.; Sangaralingham, L.R.; Shah, N.D.; Nath, K.A.; Noseworthy, P.A. Renal Outcomes in Anticoagulated Patients with Atrial Fibrillation. J. Am. Coll. Cardiol. 2017, 70, 2621–2632. [Google Scholar] [CrossRef]
  27. Lavalle, C.; Di Lullo, L.; Bellasi, A.; Ronco, C.; Radicchia, S.; Barbera, V.; Galardo, G.; Piro, A.; Magnocavallo, M.; Straito, M.; et al. Adverse Drug Reactions during Real-Life Use of Direct Oral Anticoagulants in Italy: An Update Based on Data from the Italian National Pharmacovigilance Network. Cardiorenal Med. 2020, 10, 266–276. [Google Scholar] [CrossRef]
  28. Mohanty, S.; Gianni, C.; Trivedi, C.; Gadiyaram, V.; Della Rocca, D.G.; MacDonald, B.; Horton, R.; Al-Ahmad, A.; Gibson, D.N.; Price, M.; et al. Risk of Thromboembolic Events after Percutaneous Left Atrial Appendage Ligation in Patients with Atrial Fibrillation: Long-Term Results of a Multicenter Study. Heart Rhythm 2020, 17, 175–181. [Google Scholar] [CrossRef]
  29. Mariani, M.V.; Magnocavallo, M.; Straito, M.; Piro, A.; Severino, P.; Iannucci, G.; Chimenti, C.; Mancone, M.; Rocca, D.G.D.; Forleo, G.B.; et al. Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Cancer a Meta-Analysis. J. Thromb. Thrombolysis 2020. [Google Scholar] [CrossRef]
  30. Siontis, K.C.; Zhang, X.; Eckard, A.; Bhave, N.; Schaubel, D.E.; He, K.; Tilea, A.; Stack, A.G.; Balkrishnan, R.; Yao, X.; et al. Outcomes Associated with Apixaban Use in Patients with End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation 2018, 138, 1519–1529. [Google Scholar] [CrossRef]
  31. Miao, B.; Sood, N.; Bunz, T.J.; Coleman, C.I. Rivaroxaban versus Apixaban in Non-valvular Atrial Fibrillation Patients with End-stage Renal Disease or Receiving Dialysis. Eur. J. Haematol. 2020, 104, 328–335. [Google Scholar] [CrossRef]
  32. Jha, V.; Garcia-Garcia, G.; Iseki, K.; Li, Z.; Naicker, S.; Plattner, B.; Saran, R.; Wang, A.Y.-M.; Yang, C.-W. Chronic Kidney Disease: Global Dimension and Perspectives. Lancet 2013, 382, 260–272. [Google Scholar] [CrossRef]
  33. Alonso, A.; Bengtson, L.G.S. A Rising Tide: The Global Epidemic of Atrial Fibrillation. Circulation 2014, 129, 829–830. [Google Scholar] [CrossRef] [PubMed]
  34. Zimmerman, D.; Sood, M.M.; Rigatto, C.; Holden, R.M.; Hiremath, S.; Clase, C.M. Systematic Review and Meta-Analysis of Incidence, Prevalence and Outcomes of Atrial Fibrillation in Patients on Dialysis. Nephrol. Dial. Transplant. 2012, 27, 3816–3822. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Piccini, J.P.; Stevens, S.R.; Chang, Y.; Singer, D.E.; Lokhnygina, Y.; Go, A.S.; Patel, M.R.; Mahaffey, K.W.; Halperin, J.L.; Breithardt, G.; et al. Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation: Validation of the R 2 CHADS 2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk Factors In Atrial Fibrillation) Study Cohorts. Circulation 2013, 127, 224–232. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Providência, R.; Fernandes, A.; Paiva, L.; Faustino, A.; Barra, S.; Botelho, A.; Trigo, J.; Nascimento, J.; Leitão-Marques, A. Decreased Glomerular Filtration Rate and Markers of Left Atrial Stasis in Patients with Nonvalvular Atrial Fibrillation. Cardiology 2013, 124, 3–10. [Google Scholar] [CrossRef]
  37. Kizawa, S.; Ito, T.; Akamatsu, K.; Ichihara, N.; Nogi, S.; Miyamura, M.; Kanzaki, Y.; Sohmiya, K.; Hoshiga, M. Chronic Kidney Disease as a Possible Predictor of Left Atrial Thrombogenic Milieu Among Patients with Nonvalvular Atrial Fibrillation. Am. J. Cardiol. 2018, 122, 2062–2067. [Google Scholar] [CrossRef]
  38. Yagishita, A.; Takahashi, Y.; Takahashi, A. Relationship between Transesophageal Echocar- Diographic Features and Glomerular Filtration Rate in Patients with Persistent Atrial Fibrillation. Heart Rhythm 2010, 7, S387. [Google Scholar]
  39. Gedikli, Ö.; Mohanty, S.; Trivedi, C.; Gianni, C.; Chen, Q.; Della Rocca, D.G.; Burkhardt, J.D.; Sanchez, J.E.; Hranitzky, P.; Gallinghouse, G.J.; et al. Impact of Dense “Smoke” Detected on Transesophageal Echocardiography on Stroke Risk in Patients with Atrial Fibrillation Undergoing Catheter Ablation. Heart Rhythm 2019, 16, 351–357. [Google Scholar] [CrossRef]
  40. Wang, M.-C.; Tsai, W.-C.; Chen, J.-Y.; Huang, J.-J. Stepwise Increase in Arterial Stiffness Corresponding with the Stages of Chronic Kidney Disease. Am. J. Kidney Dis. 2005, 45, 494–501. [Google Scholar] [CrossRef]
  41. Bolton, C.H.; Downs, L.G.; Victory, J.G.; Dwight, J.F.; Tomson, C.R.; Mackness, M.I.; Pinkney, J.H. Endothelial Dysfunction in Chronic Renal Failure: Roles of Lipoprotein Oxidation and pro-Inflammatory Cytokines. Nephrol. Dial. Transplant. 2001, 16, 1189–1197. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Heintz, B.; Schmidt, P.; Maurin, N.; Kirsten, R.; Nelson, K.; Wieland, D.; Sieberth, H.-G. Endothelin-1 Potentiates ADP-Induced Platelet Aggregation in Chronic Renal Failure. Ren. Fail. 1994, 16, 481–489. [Google Scholar] [CrossRef] [PubMed]
  43. Della Rocca, D.G.; Pepine, C.J. Some Thoughts on the Continuing Dilemma of Angina Pectoris. Eur. Heart J. 2014, 35, 1361–1364. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Della Rocca, D.G.; Pepine, C.J. Endothelium as a Predictor of Adverse Outcomes: Endothelium as a Predictor of Adverse Outcomes. Clin. Cardiol. 2010, 33, 730–732. [Google Scholar] [CrossRef]
  45. Tomura, S.; Nakamura, Y.; Doi, M.; Ando, R.; Ida, T.; Chida, Y.; Ootsuka, S.; Shinoda, T.; Yanagi, H.; Tsuchiya, S.; et al. Fibrinogen, Coagulation Factor VII, Tissue Plasminogen Activator, Plasminogen Activator Inhibitor-1, and Lipid as Cardiovascular Risk Factors in Chronic Hemodialysis and Continuous Ambulatory Peritoneal Dialysis Patients. Am. J. Kidney Dis. 1996, 27, 848–854. [Google Scholar] [CrossRef]
  46. Shlipak, M.G.; Fried, L.F.; Crump, C.; Bleyer, A.J.; Manolio, T.A.; Tracy, R.P.; Furberg, C.D.; Psaty, B.M. Elevations of Inflammatory and Procoagulant Biomarkers in Elderly Persons with Renal Insufficiency. Circulation 2003, 107, 87–92. [Google Scholar] [CrossRef] [Green Version]
  47. Costa, E.; Rocha, S.; Rocha-Pereira, P.; Castro, E.; Reis, F.; Teixeira, F.; Miranda, V.; Do Sameiro Faria, M.; Loureiro, A.; Quintanilha, A.; et al. Cross-Talk between Inflammation, Coagulation/Fibrinolysis and Vascular Access in Hemodialysis Patients. J. Vasc. Access 2008, 9, 248–253. [Google Scholar] [CrossRef] [Green Version]
  48. Keller, C.; Katz, R.; Cushman, M.; Fried, L.F.; Shlipak, M. Association of Kidney Function with Inflammatory and Procoagulant Markers in a Diverse Cohort: A Cross-Sectional Analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol. 2008, 9, 9. [Google Scholar] [CrossRef]
  49. Kaw, D.; Malhotra, D. Platelet Dysfunction and End-Stage Renal Disease. Semin. Dial. 2006, 19, 317–322. [Google Scholar] [CrossRef]
  50. Boccardo, P.; Remuzzi, G.; Galbusera, M. Platelet Dysfunction in Renal Failure. Semin. Thromb. Hemost. 2004, 30, 579–589. [Google Scholar] [CrossRef]
  51. Mannucci, P.M.; Tripodi, A. Hemostatic Defects in Liver and Renal Dysfunction. Hematol. Am. Soc. Hematol. Educ. Program. 2012, 2012, 168–173. [Google Scholar] [CrossRef]
  52. Reinecke, H.; Brand, E.; Mesters, R.; Schäbitz, W.-R.; Fisher, M.; Pavenstädt, H.; Breithardt, G. Dilemmas in the Management of Atrial Fibrillation in Chronic Kidney Disease. J. Am. Soc. Nephrol. 2009, 20, 705–711. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Ravera, M.; Bussalino, E.; Paoletti, E.; Bellasi, A.; Di Lullo, L.; Fusaro, M. Haemorragic and Thromboembolic Risk in CKD Patients with Non Valvular Atrial Fibrillation: Do We Need a Novel Risk Score Calculator? Int. J. Cardiol. 2019, 274, 179–185. [Google Scholar] [CrossRef] [PubMed]
  54. Brodsky, S.V.; Satoskar, A.; Chen, J.; Nadasdy, G.; Eagen, J.W.; Hamirani, M.; Hebert, L.; Calomeni, E.; Nadasdy, T. Acute Kidney Injury During Warfarin Therapy Associated with Obstructive Tubular Red Blood Cell Casts: A Report of 9 Cases. Am. J. Kidney Dis. 2009, 54, 1121–1126. [Google Scholar] [CrossRef] [PubMed]
  55. Brodsky, S.V.; Nadasdy, T.; Rovin, B.H.; Satoskar, A.A.; Nadasdy, G.M.; Wu, H.M.; Bhatt, U.Y.; Hebert, L.A. Warfarin-Related Nephropathy Occurs in Patients with and without Chronic Kidney Disease and Is Associated with an Increased Mortality Rate. Kidney Int. 2011, 80, 181–189. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Brodsky, S.; Eikelboom, J.; Hebert, L.A. Anticoagulant-Related Nephropathy. J. Am. Soc. Nephrol. 2018, 29, 2787–2793. [Google Scholar] [CrossRef] [Green Version]
  57. Piran, S.; Traquair, H.; Chan, N.; Robinson, M.; Schulman, S. Incidence and Risk Factors for Acute Kidney Injury in Patients with Excessive Anticoagulation on Warfarin: A Retrospective Study. J. Thromb. Thrombolysis 2018, 45, 557–561. [Google Scholar] [CrossRef]
  58. De Aquino Moura, K.B.; Behrens, P.M.P.; Pirolli, R.; Sauer, A.; Melamed, D.; Veronese, F.V.; da Silva, A.L.F.A. Anticoagulant-Related Nephropathy: Systematic Review and Meta-Analysis. Clin. Kidney J. 2019, 12, 400–407. [Google Scholar] [CrossRef] [Green Version]
  59. Ware, K.; Brodsky, P.; Satoskar, A.A.; Nadasdy, T.; Nadasdy, G.; Wu, H.; Rovin, B.H.; Bhatt, U.; Von Visger, J.; Hebert, L.A.; et al. Warfarin-Related Nephropathy Modeled by Nephron Reduction and Excessive Anticoagulation. J. Am. Soc. Nephrol. 2011, 22, 1856–1862. [Google Scholar] [CrossRef] [Green Version]
  60. Golbin, L.; Vigneau, C.; Touchard, G.; Thervet, E.; Halimi, J.; Sawadogo, T.; Lagoutte, N.; Siohan, P.; Zagdoun, E.; Hertig, A.; et al. Warfarin-Related Nephropathy Induced by Three Different Vitamin K Antagonists: Analysis of 13 Biopsy-Proven Cases. Clin. Kidney J. 2017, 10, 381–388. [Google Scholar] [CrossRef] [Green Version]
  61. Zeni, L.; Manenti, C.; Fisogni, S.; Terlizzi, V.; Verzeletti, F.; Gaggiotti, M.; Cancarini, G. Acute Kidney Injury Due to Anticoagulant-Related Nephropathy : A Suggestion for Therapy. Case Rep. Nephrol. 2020, 2020, 8952670. [Google Scholar] [CrossRef] [PubMed]
  62. Escoli, R.; Santos, P.; Andrade, S.; Carvalho, F. Dabigatran-Related Nephropathy in a Patient with Undiagnosed IgA Nephropathy. Case Rep. Nephrol. 2015, 2015, 1–4. [Google Scholar] [CrossRef] [Green Version]
  63. Ryan, M.; Ware, K.; Qamri, Z.; Satoskar, A.; Wu, H.; Nadasdy, G.; Rovin, B.; Hebert, L.; Nadasdy, T.; Brodsky, S.V. Warfarin-Related Nephropathy Is the Tip of the Iceberg: Direct Thrombin Inhibitor Dabigatran Induces Glomerular Hemorrhage with Acute Kidney Injury in Rats. Nephrol. Dial. Transplant. 2014, 29, 2228–2234. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Zhang, C.; Gu, Z.-C.; Ding, Z.; Shen, L.; Pan, M.-M.; Zheng, Y.-L.; Lin, H.-W.; Pu, J. Decreased Risk of Renal Impairment in Atrial Fibrillation Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants: A Pooled Analysis of Randomized Controlled Trials and Real-World Studies. Thromb. Res. 2019, 174, 16–23. [Google Scholar] [CrossRef]
  65. Chan, Y.-H.; See, L.-C.; Tu, H.-T.; Yeh, Y.-H.; Chang, S.-H.; Wu, L.-S.; Lee, H.-F.; Wang, C.-L.; Kuo, C.-F.; Kuo, C.-T. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation. J. Am. Heart Assoc. 2018, 7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Price, P.A.; Faus, S.A.; Williamson, M.K. Warfarin Causes Rapid Calcification of the Elastic Lamellae in Rat Arteries and Heart Valves. Arterioscler. Thromb. Vasc. Biol. 1998, 18, 1400–1407. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  67. Rennenberg, R.J.M.W.; van Varik, B.J.; Schurgers, L.J.; Hamulyak, K.; ten Cate, H.; Leiner, T.; Vermeer, C.; de Leeuw, P.W.; Kroon, A.A. Chronic Coumarin Treatment Is Associated with Increased Extracoronary Arterial Calcification in Humans. Blood 2010, 115, 5121–5123. [Google Scholar] [CrossRef] [Green Version]
  68. Della Rocca, D.G.; Santini, L.; Forleo, G.B.; Sanniti, A.; Del Prete, A.; Lavalle, C.; Di Biase, L.; Natale, A.; Romeo, F. Novel Perspectives on Arrhythmia-Induced Cardiomyopathy: Pathophysiology, Clinical Manifestations and an Update on Invasive Management Strategies. Cardiol. Rev. 2015, 23, 135–141. [Google Scholar] [CrossRef]
  69. Tantisattamo, E.; Han, K.H.; O’Neill, W.C. Increased Vascular Calcification in Patients Receiving Warfarin. Arterioscler. Thromb. Vasc. Biol. 2015, 35, 237–242. [Google Scholar] [CrossRef] [Green Version]
  70. Han, K.H.; O’Neill, W.C. Increased Peripheral Arterial Calcification in Patients Receiving Warfarin. J. Am. Heart Assoc. 2016, 5. [Google Scholar] [CrossRef] [Green Version]
  71. Montone, R.A.; Niccoli, G.; Tufaro, V.; Minelli, S.; Russo, M.; Vergni, F.; Sommariva, L.; Pelliccia, F.; Bedogni, F.; Crea, F. Changes in Renal Function and Occurrence of Contrast-Induced Nephropathy after Percutaneous Coronary Interventions in Patients with Atrial Fibrillation Treated with Non-Vitamin K Oral Anticoagulants or Warfarin. Postepy W Kardiologii Interwencyjnej Adv. Interv. Cardiol. 2019, 15, 59–67. [Google Scholar] [CrossRef] [PubMed]
  72. Yao, X.; Inselman, J.W.; Ross, J.S.; Izem, R.; Graham, D.J.; Martin, D.B.; Thompson, A.M.; Ross Southworth, M.; Siontis, K.C.; Ngufor, C.G.; et al. Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients with Atrial Fibrillation. Circ. Cardiovasc. Qual. Outcomes 2020, 13. [Google Scholar] [CrossRef] [PubMed]
  73. Bohula, E.A.; Giugliano, R.P.; Ruff, C.T.; Kuder, J.F.; Murphy, S.A.; Antman, E.M.; Braunwald, E. Impact of Renal Function on Outcomes with Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation 2016, 134, 24–36. [Google Scholar] [CrossRef] [PubMed]
  74. Fauchier, L.; Bisson, A.; Clementy, N.; Vourc’h, P.; Angoulvant, D.; Babuty, D.; Halimi, J.M.; Lip, G.Y.H. Changes in Glomerular Filtration Rate and Outcomes in Patients with Atrial Fibrillation. Am. Heart J. 2018, 198, 39–45. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Banerjee, A.; Fauchier, L.; Vourc’h, P.; Andres, C.R.; Taillandier, S.; Halimi, J.M.; Lip, G.Y.H. A Prospective Study of Estimated Glomerular Filtration Rate and Outcomes in Patients with Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project. Chest 2014, 145, 1370–1382. [Google Scholar] [CrossRef]
  76. Pecoits-Filho, R.; Abensur, H.; Betônico, C.C.R.; Machado, A.D.; Parente, E.B.; Queiroz, M.; Salles, J.E.N.; Titan, S.; Vencio, S. Interactions between Kidney Disease and Diabetes: Dangerous Liaisons. Diabetol. Metab. Syndr. 2016, 8, 50. [Google Scholar] [CrossRef]
  77. United States Renal Data System. 2019 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States; United States Renal Data System: Bethesda, MD, USA, 2019. [Google Scholar]
  78. Fox, C.S. Predictors of New-Onset Kidney Disease in a Community-Based Population. JAMA 2004, 291, 844. [Google Scholar] [CrossRef] [Green Version]
  79. De Boer, I.H. Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States. JAMA 2011, 305, 2532. [Google Scholar] [CrossRef]
  80. Beckman, J.A.; Creager, M.A.; Libby, P. Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management. JAMA 2002, 287, 2570. [Google Scholar] [CrossRef]
  81. Franchi, F.; James, S.K.; Ghukasyan Lakic, T.; Budaj, A.J.; Cornel, J.H.; Katus, H.A.; Keltai, M.; Kontny, F.; Lewis, B.S.; Storey, R.F.; et al. Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y 12 Receptor Antagonist Effects in Patients with Acute Coronary Syndromes: Insights from the PLATO Trial. J. Am. Heart Assoc. 2019, 8. [Google Scholar] [CrossRef] [Green Version]
  82. Ferreiro, J.L.; Angiolillo, D.J. Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome. Circulation 2011, 123, 798–813. [Google Scholar] [CrossRef] [PubMed]
  83. Bonello, L.; Angiolillo, D.J.; Aradi, D.; Sibbing, D. P2Y12-ADP Receptor Blockade in Chronic Kidney Disease Patients with Acute Coronary Syndromes. Circulation 2018, 138, 1582–1596. [Google Scholar] [CrossRef] [PubMed]
  84. Baber, U.; Chandrasekhar, J.; Sartori, S.; Aquino, M.; Kini, A.S.; Kapadia, S.; Weintraub, W.; Muhlestein, J.B.; Vogel, B.; Faggioni, M.; et al. Associations Between Chronic Kidney Disease and Outcomes with Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JACC Cardiovasc. Interv. 2017, 10, 2017–2025. [Google Scholar] [CrossRef] [PubMed]
  85. Desai, R.J.; Spoendlin, J.; Mogun, H.; Gagne, J.J. Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease. Pharmacotherapy 2017, 37, 1322–1327. [Google Scholar] [CrossRef] [PubMed]
  86. Abe, M.; Kalantar-Zadeh, K. Haemodialysis-Induced Hypoglycaemia and Glycaemic Disarrays. Nat. Rev. Nephrol. 2015, 11, 302–313. [Google Scholar] [CrossRef]
  87. Meyer, C.; Gerich, J.E. Role of the Kidney in Hyperglycemia in Type 2 Diabetes. Curr. Diab. Rep. 2002, 2, 237–241. [Google Scholar] [CrossRef]
  88. Ravera, M.; Bussalino, E.; Fusaro, M.; Di Lullo, L.; Aucella, F.; Paoletti, E. Systematic DOACs Oral Anticoagulation in Patients with Atrial Fibrillation and Chronic Kidney Disease: The Nephrologist’s Perspective. J. Nephrol. 2020, 33, 483–495. [Google Scholar] [CrossRef]
  89. Posch, F.; Ay, C.; Stöger, H.; Kreutz, R.; Beyer-Westendorf, J. Exposure to Vitamin k Antagonists and Kidney Function Decline in Patients with Atrial Fibrillation and Chronic Kidney Disease. Res. Pract. Thromb. Haemost. 2019, 3, 207–216. [Google Scholar] [CrossRef] [Green Version]
  90. Fusaro, M.; Gallieni, M.; Aghi, A.; Rizzo, M.A.; Iervasi, G.; Nickolas, T.L.; Fabris, F.; Mereu, M.C.; Giannini, S.; Sella, S.; et al. Osteocalcin (Bone GLA Protein) Levels, Vascular Calcifications, Vertebral Fractures and Mortality in Hemodialysis Patients with Diabetes Mellitus. J. Nephrol. 2019, 32, 635–643. [Google Scholar] [CrossRef]
  91. Schurgers, L.J.; Joosen, I.A.; Laufer, E.M.; Chatrou, M.L.L.; Herfs, M.; Winkens, M.H.M.; Westenfeld, R.; Veulemans, V.; Krueger, T.; Shanahan, C.M.; et al. Vitamin K-Antagonists Accelerate Atherosclerotic Calcification and Induce a Vulnerable Plaque Phenotype. PLoS ONE 2012, 7, e43229. [Google Scholar] [CrossRef] [Green Version]
  92. Price, P.A.; Fraser, J.D.; Metz-Virca, G. Molecular Cloning of Matrix Gla Protein: Implications for Substrate Recognition by the Vitamin K-Dependent Gamma-Carboxylase. Proc. Natl. Acad. Sci. USA 1987, 84, 8335–8339. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Chatrou, M.L.L.; Winckers, K.; Hackeng, T.M.; Reutelingsperger, C.P.; Schurgers, L.J. Vascular Calcification: The Price to Pay for Anticoagulation Therapy with Vitamin K-Antagonists. Blood Rev. 2012, 26, 155–166. [Google Scholar] [CrossRef] [PubMed]
  94. Parker, B.D.; Ix, J.H.; Cranenburg, E.C.M.; Vermeer, C.; Whooley, M.A.; Schurgers, L.J. Association of Kidney Function and Uncarboxylated Matrix Gla Protein: Data from the Heart and Soul Study. Nephrol. Dial. Transplant. 2009, 24, 2095–2101. [Google Scholar] [CrossRef] [PubMed]
  95. Hernandez, A.V.; Bradley, G.; Khan, M.; Fratoni, A.; Gasparini, A.; Roman, Y.M.; Bunz, T.J.; Eriksson, D.; Meinecke, A.-K.; Coleman, C.I. Rivaroxaban Versus Warfarin and Renal Outcomes in Non-Valvular Atrial Fibrillation Patients with Diabetes. Eur. Heart J. Qual. Care Clin. Outcomes 2019. [Google Scholar] [CrossRef]
  96. Fordyce, C.B.; Hellkamp, A.S.; Lokhnygina, Y.; Lindner, S.M.; Piccini, J.P.; Becker, R.C.; Berkowitz, S.D.; Breithardt, G.; Fox, K.A.A.; Mahaffey, K.W.; et al. On-Treatment Outcomes in Patients with Worsening Renal Function with Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Circulation 2016, 134, 37–47. [Google Scholar] [CrossRef] [Green Version]
  97. O’Brien, E.C.; Simon, D.N.; Allen, L.A.; Singer, D.E.; Fonarow, G.C.; Kowey, P.R.; Thomas, L.E.; Ezekowitz, M.D.; Mahaffey, K.W.; Chang, P.; et al. Reasons for Warfarin Discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am. Heart J. 2014, 168, 487–494. [Google Scholar] [CrossRef]
  98. Liesenfeld, K.-H.; Clemens, A.; Kreuzer, J.; Brueckmann, M.; Schulze, F. Dabigatran Treatment Simulation in Patients Undergoing Maintenance Haemodialysis. Thromb. Haemost. 2016, 115, 562–569. [Google Scholar] [CrossRef]
  99. Wang, X.; Tirucherai, G.; Marbury, T.C.; Wang, J.; Chang, M.; Zhang, D.; Song, Y.; Pursley, J.; Boyd, R.A.; Frost, C. Pharmacokinetics, Pharmacodynamics, and Safety of Apixaban in Subjects with End-Stage Renal Disease on Hemodialysis. J. Clin. Pharmacol. 2016, 56, 628–636. [Google Scholar] [CrossRef] [Green Version]
  100. Mavrakanas, T.A.; Samer, C.F.; Nessim, S.J.; Frisch, G.; Lipman, M.L. Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. J. Am. Soc. Nephrol. 2017, 28, 2241–2248. [Google Scholar] [CrossRef]
  101. De Vriese, A.S.; Caluwé, R.; Bailleul, E.; De Bacquer, D.; Borrey, D.; Van Vlem, B.; Vandecasteele, S.J.; Emmerechts, J. Dose-Finding Study of Rivaroxaban in Hemodialysis Patients. Am. J. Kidney Dis. 2015, 66, 91–98. [Google Scholar] [CrossRef]
  102. Dias, C.; Moore, K.T.; Murphy, J.; Ariyawansa, J.; Smith, W.; Mills, R.M.; Weir, M.R. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis. Am. J. Nephrol. 2016, 43, 229–236. [Google Scholar] [CrossRef]
  103. See, L.-C.; Lee, H.-F.; Chao, T.-F.; Li, P.-R.; Liu, J.-R.; Wu, L.-S.; Chang, S.-H.; Yeh, Y.-H.; Kuo, C.-T.; Chan, Y.-H.; et al. Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis. Cardiovasc. Drugs Ther. 2020. [Google Scholar] [CrossRef]
  104. Coleman, C.I.; Kreutz, R.; Sood, N.A.; Bunz, T.J.; Eriksson, D.; Meinecke, A.-K.; Baker, W.L. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. Am. J. Med. 2019, 132, 1078–1083. [Google Scholar] [CrossRef] [PubMed]
  105. Kuno, T.; Takagi, H.; Ando, T.; Sugiyama, T.; Miyashita, S.; Valentin, N.; Shimada, Y.J.; Kodaira, M.; Numasawa, Y.; Briasoulis, A.; et al. Oral Anticoagulation for Patients with Atrial Fibrillation on Long-Term Hemodialysis. J. Am. Coll. Cardiol. 2020, 75, 273–285. [Google Scholar] [CrossRef] [PubMed]
  106. Chokesuwattanaskul, R.; Thongprayoon, C.; Tanawuttiwat, T.; Kaewput, W.; Pachariyanon, P.; Cheungpasitporn, W. Safety and Efficacy of Apixaban versus Warfarin in Patients with End-Stage Renal Disease: Meta-Analysis. Pacing Clin. Electrophysiol. 2018, 41, 627–634. [Google Scholar] [CrossRef] [PubMed]
  107. Wanner, C.; Herzog, C.A.; Turakhia, M.P.; Blankestijn, P.J.; Carrero, J.-J.; Clase, C.M.; Deo, R.; Kasner, S.E.; Passman, R.S.; Pecoits-Filho, R.; et al. Chronic Kidney Disease and Arrhythmias: Highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2018, 94, 231–234. [Google Scholar] [CrossRef]
  108. Reinecke, H.; Jürgensmeyer, S.; Engelbertz, C.; Gerss, J.; Kirchhof, P.; Breithardt, G.; Bauersachs, R.; Wanner, C. Design and Rationale of a Randomised Controlled Trial Comparing Apixaban to Phenprocoumon in Patients with Atrial Fibrillation on Chronic Haemodialysis: The AXADIA-AFNET 8 Study. BMJ Open 2018, 8, e022690. [Google Scholar] [CrossRef]
  109. Beinema, M.; Brouwers, J.R.B.J.; Schalekamp, T.; Wilffert, B. Pharmacogenetic Differences between Warfarin, Acenocoumarol and Phenprocoumon. Thromb. Haemost. 2008, 100, 1052–1057. [Google Scholar]
  110. Ufer, M. Comparative Pharmacokinetics of Vitamin K Antagonists: Warfarin, Phenprocoumon and Acenocoumarol. Clin. Pharmacokinet. 2005, 44, 1227–1246. [Google Scholar] [CrossRef]
  111. Di Lullo, L.; Tripepi, G.; Ronco, C.; D’Arrigo, G.; Barbera, V.; Russo, D.; Di Iorio, B.R.; Uguccioni, M.; Paoletti, E.; Ravera, M.; et al. Cardiac Valve Calcification and Use of Anticoagulants: Preliminary Observation of a Potentially Modifiable Risk Factor. Int. J. Cardiol. 2019, 278, 243–249. [Google Scholar] [CrossRef]
  112. Genovesi, S.; Rossi, E.; Gallieni, M.; Stella, A.; Badiali, F.; Conte, F.; Pasquali, S.; Bertoli, S.; Ondei, P.; Bonforte, G.; et al. Warfarin Use, Mortality, Bleeding and Stroke in Haemodialysis Patients with Atrial Fibrillation. Nephrol. Dial. Transplant. 2015, 30, 491–498. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  113. Holbrook, A.M.; Pereira, J.A.; Labiris, R.; McDonald, H.; Douketis, J.D.; Crowther, M.; Wells, P.S. Systematic Overview of Warfarin and Its Drug and Food Interactions. Arch. Intern. Med. 2005, 165, 1095–1106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  114. Esteve-Pastor, M.A.; Rivera-Caravaca, J.M.; Roldán-Rabadán, I.; Roldán, V.; Muñiz, J.; Raña-Míguez, P.; Ruiz-Ortiz, M.; Cequier, Á.; Bertomeu-Martínez, V.; Badimón, L.; et al. Quality of Oral Anticoagulation with Vitamin K Antagonists in ‘Real-World’ Patients with Atrial Fibrillation: A Report from the Prospective Multicentre FANTASIIA Registry. EP Eur. 2018, 20, 1435–1441. [Google Scholar] [CrossRef] [PubMed]
  115. Korenstra, J.; Wijtvliet, E.P.J.; Veeger, N.J.G.M.; Geluk, C.A.; Bartels, G.L.; Posma, J.L.; Piersma-Wichers, M.; Van Gelder, I.C.; Rienstra, M.; Tieleman, R.G. Effectiveness and Safety of Dabigatran versus Acenocoumarol in ‘Real-World’ Patients with Atrial Fibrillation. Europace 2016, 18, 1319–1327. [Google Scholar] [CrossRef] [PubMed]
  116. Pokorney, S.D.; Simon, D.N.; Thomas, L.; Gersh, B.J.; Hylek, E.M.; Piccini, J.P.; Peterson, E.D. Stability of International Normalized Ratios in Patients Taking Long-Term Warfarin Therapy. JAMA 2016, 316, 661. [Google Scholar] [CrossRef] [PubMed]
  117. Dahal, K.; Kunwar, S.; Rijal, J.; Schulman, P.; Lee, J. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users with Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. Chest 2016, 149, 951–959. [Google Scholar] [CrossRef]
  118. Martinez, C.; Katholing, A.; Wallenhorst, C.; Freedman, S.B. Therapy Persistence in Newly Diagnosed Non-Valvular Atrial Fibrillation Treated with Warfarin or NOAC. A Cohort Study. Thromb. Haemost. 2016, 115, 31–39. [Google Scholar] [CrossRef]
  119. Benzimra, M.; Bonnamour, B.; Duracinsky, M.; Lalanne, C.; Aubert, J.-P.; Chassany, O.; Aubin-Auger, I.; Mahé, I. Real-Life Experience of Quality of Life, Treatment Satisfaction, and Adherence in Patients Receiving Oral Anticoagulants for Atrial Fibrillation. Patient Prefer. Adherence 2018, 12, 79–87. [Google Scholar] [CrossRef] [Green Version]
  120. Kim, H.; Lee, Y.S.; Kim, T.-H.; Cha, M.-J.; Lee, J.M.; Park, J.; Park, J.-K.; Kang, K.-W.; Shim, J.; Uhm, J.-S.; et al. A Prospective Survey of the Persistence of Warfarin or NOAC in Nonvalvular Atrial Fibrillation: A COmparison Study of Drugs for Symptom Control and Complication PrEvention of Atrial Fibrillation (CODE-AF). Korean J. Intern. Med. 2020, 35, 99–108. [Google Scholar] [CrossRef]
  121. Blackshear, J.L.; Odell, J.A. Appendage Obliteration to Reduce Stroke in Cardiac Surgical Patients with Atrial Fibrillation. Ann. Thorac. Surg. 1996, 61, 755–759. [Google Scholar] [CrossRef]
  122. Boersma, L.V.A.; Schmidt, B.; Betts, T.R.; Sievert, H.; Tamburino, C.; Teiger, E.; Pokushalov, E.; Kische, S.; Schmitz, T.; Stein, K.M.; et al. Implant Success and Safety of Left Atrial Appendage Closure with the WATCHMAN Device: Peri-Procedural Outcomes from the EWOLUTION Registry. Eur. Heart J. 2016, 37, 2465–2474. [Google Scholar] [CrossRef] [PubMed]
  123. Tzikas, A.; Shakir, S.; Gafoor, S.; Omran, H.; Berti, S.; Santoro, G.; Kefer, J.; Landmesser, U.; Nielsen-Kudsk, J.E.; Cruz-Gonzalez, I.; et al. Left Atrial Appendage Occlusion for Stroke Prevention in Atrial Fibrillation: Multicentre Experience with the AMPLATZER Cardiac Plug. EuroIntervention 2016, 11, 1170–1179. [Google Scholar] [CrossRef] [PubMed]
  124. Lakkireddy, D.; Afzal, M.R.; Lee, R.J.; Nagaraj, H.; Tschopp, D.; Gidney, B.; Ellis, C.; Altman, E.; Lee, B.; Kar, S.; et al. Short and Long-Term Outcomes of Percutaneous Left Atrial Appendage Suture Ligation: Results from a US Multicenter Evaluation. Heart Rhythm 2016, 13, 1030–1036. [Google Scholar] [CrossRef] [PubMed]
  125. Gianni, C.; Anannab, A.; Sahore Salwan, A.; Della Rocca, D.G.; Natale, A.; Horton, R.P. Closure of the Left Atrial Appendage Using Percutaneous Transcatheter Occlusion Devices. J. Cardiovasc. Electrophysiol. 2020, 31, 2179–2186. [Google Scholar] [CrossRef] [PubMed]
  126. Holmes, D.R.; Kar, S.; Price, M.J.; Whisenant, B.; Sievert, H.; Doshi, S.K.; Huber, K.; Reddy, V.Y. Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients with Atrial Fibrillation versus Long-Term Warfarin Therapy: The PREVAIL Trial. J. Am. Coll. Cardiol. 2014, 64, 1–12. [Google Scholar] [CrossRef] [Green Version]
  127. Reddy, V.Y.; Doshi, S.K.; Sievert, H.; Buchbinder, M.; Neuzil, P.; Huber, K.; Halperin, J.L.; Holmes, D. PROTECT AF Investigators Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients with Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013, 127, 720–729. [Google Scholar] [CrossRef] [Green Version]
  128. Gadiyaram, V.K.; Mohanty, S.; Gianni, C.; Trivedi, C.; Al-Ahmad, A.; Burkhardt, D.J.; Gallinghouse, J.G.; Hranitzky, P.M.; Horton, R.P.; Sanchez, J.E.; et al. Thromboembolic Events and Need for Anticoagulation Therapy Following Left Atrial Appendage Occlusion in Patients with Electrical Isolation of the Appendage. J. Cardiovasc. Electrophysiol. 2019, 30, 511–516. [Google Scholar] [CrossRef]
  129. Della Rocca, D.G.; Horton, R.P.; Di Biase, L.; Bassiouny, M.; Al-Ahmad, A.; Mohanty, S.; Gasperetti, A.; Natale, V.N.; Trivedi, C.; Gianni, C.; et al. First Experience of Transcatheter Leak Occlusion with Detachable Coils Following Left Atrial Appendage Closure. JACC Cardiovasc. Interv. 2020, 13, 306–319. [Google Scholar] [CrossRef]
  130. Sedaghat, A.; Vij, V.; Streit, S.R.; Schrickel, J.W.; Al-Kassou, B.; Nelles, D.; Kleinecke, C.; Windecker, S.; Meier, B.; Valglimigli, M.; et al. Incidence, Predictors, and Relevance of Acute Kidney Injury in Patients Undergoing Left Atrial Appendage Closure with Amplatzer Occluders: A Multicentre Observational Study. Clin. Res. Cardiol. 2020, 109, 444–453. [Google Scholar] [CrossRef]
  131. Kefer, J.; Tzikas, A.; Freixa, X.; Shakir, S.; Gafoor, S.; Nielsen-Kudsk, J.E.; Berti, S.; Santoro, G.; Aminian, A.; Landmesser, U.; et al. Impact of Chronic Kidney Disease on Left Atrial Appendage Occlusion for Stroke Prevention in Patients with Atrial Fibrillation. Int. J. Cardiol. 2016, 207, 335–340. [Google Scholar] [CrossRef]
  132. Luani, B.; Genz, C.; Herold, J.; Mitrasch, A.; Mitusch, J.; Wiemer, M.; Schmeißer, A.; Braun-Dullaeus, R.C.; Rauwolf, T. Cerebrovascular Events, Bleeding Complications and Device Related Thrombi in Atrial Fibrillation Patients with Chronic Kidney Disease and Left Atrial Appendage Closure with the WATCHMANTM Device. BMC Cardiovasc. Disord. 2019, 19, 112. [Google Scholar] [CrossRef] [PubMed]
  133. Cruz-González, I.; Trejo-Velasco, B.; Fraile, M.P.; Barreiro-Pérez, M.; González-Ferreiro, R.; Sánchez, P.L. Left Atrial Appendage Occlusion in Hemodialysis Patients: Initial Experience. Rev. Espanola Cardiol. Engl. Ed. 2019, 72, 792–793. [Google Scholar] [CrossRef]
  134. Genovesi, S.; Porcu, L.; Slaviero, G.; Casu, G.; Bertoli, S.; Sagone, A.; Buskermolen, M.; Pieruzzi, F.; Rovaris, G.; Montoli, A.; et al. Outcomes on Safety and Efficacy of Left Atrial Appendage Occlusion in End Stage Renal Disease Patients Undergoing Dialysis. J. Nephrol. 2020. [Google Scholar] [CrossRef]
  135. Xue, X.; Jiang, L.; Duenninger, E.; Muenzel, M.; Guan, S.; Fazakas, A.; Cheng, F.; Illnitzky, J.; Keil, T.; Yu, J. Impact of Chronic Kidney Disease on Watchman Implantation: Experience with 300 Consecutive Left Atrial Appendage Closures at a Single Center. Heart Vessel. 2018, 33, 1068–1075. [Google Scholar] [CrossRef] [Green Version]
  136. Della Rocca, D.G.; Horton, R.P.; Tarantino, N.; Van Niekerk, C.J.; Trivedi, C.; Chen, Q.; Mohanty, S.; Anannab, A.; Murtaza, G.; Akella, K.; et al. Use of a Novel Septal Occluder Device for Left Atrial Appendage Closure in Patients with Postsurgical and Postlariat Leaks or Anatomies Unsuitable for Conventional Percutaneous Occlusion. Circ. Cardiovasc. Interv. 2020, 13, e009227. [Google Scholar] [CrossRef]
  137. Ayhan, H.; Mohanty, S.; Gedikli, Ö.; Trivedi, C.; Canpolat, U.; Tapia, A.C.; Chen, Q.; Della Rocca, D.G.; Gianni, C.; Salwan, A.; et al. A Simple Method to Detect Leaks after Left Atrial Appendage Occlusion with Watchman. J. Cardiovasc. Electrophysiol. 2020, 31, 2338–2343. [Google Scholar] [CrossRef]
Jcm 10 00083 g001 550
Figure 1. Prevalence of atrial fibrillation (AF) in chronic kidney disease (CKD) patients and vice versa.
Figure 1. Prevalence of atrial fibrillation (AF) in chronic kidney disease (CKD) patients and vice versa.
Jcm 10 00083 g001
Jcm 10 00083 g002 550
Figure 2. Factors increasing the propensity of thrombus formation in CKD patients.
Figure 2. Factors increasing the propensity of thrombus formation in CKD patients.
Jcm 10 00083 g002
Jcm 10 00083 g003 550
Figure 3. Factors contributing to pro-hemorrhagic state in CKD patients.
Figure 3. Factors contributing to pro-hemorrhagic state in CKD patients.
Jcm 10 00083 g003
Jcm 10 00083 g004 550
Figure 4. Comparison between direct oral anticoagulants (DOACs) and warfarin in terms of renal preservation.
Figure 4. Comparison between direct oral anticoagulants (DOACs) and warfarin in terms of renal preservation.
Jcm 10 00083 g004
Jcm 10 00083 g005 550
Figure 5. Vascular calcification, arterial and renal damage induced by inhibition of vitamin-K-dependent MGP.
Figure 5. Vascular calcification, arterial and renal damage induced by inhibition of vitamin-K-dependent MGP.
Jcm 10 00083 g005
Jcm 10 00083 g006 550
Figure 6. Pathophysiology of diabetic kidney disease. DAG: diacylglycerol; PKC: protein kinase C; ROS: reactive oxygen species.
Figure 6. Pathophysiology of diabetic kidney disease. DAG: diacylglycerol; PKC: protein kinase C; ROS: reactive oxygen species.
Jcm 10 00083 g006
Jcm 10 00083 g007 550
Figure 7. Comparison between DOACs and Warfarin in terms of renal preservation in diabetic patients.
Figure 7. Comparison between DOACs and Warfarin in terms of renal preservation in diabetic patients.
Jcm 10 00083 g007
Jcm 10 00083 g008 550
Figure 8. DOACs vs. warfarin in non-valvular AF patients with advanced kidney disease or undergoing dialysis.
Figure 8. DOACs vs. warfarin in non-valvular AF patients with advanced kidney disease or undergoing dialysis.
Jcm 10 00083 g008
Table
Table 1. Stages of CKD according to eGFR. CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; ESRD: end stage renal disease.
Table 1. Stages of CKD according to eGFR. CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; ESRD: end stage renal disease.
Stage Description eGFR (mL/min/1.73m2)
1Normal or High>90
2Mildly decrease60–89
3aMildly to
moderately decreased		45–59
3bModerately to
severely decreased		30–44
4Severely decreased15–29
5Renal failure (ESRD)<15 or dialysis
CDK is defined as either kidney damage or eGFR < 60 mL/min/1.73 m2 for ≥3 months.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Magnocavallo, M.; Bellasi, A.; Mariani, M.V.; Fusaro, M.; Ravera, M.; Paoletti, E.; Di Iorio, B.; Barbera, V.; Della Rocca, D.G.; Palumbo, R.; et al. Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy. J. Clin. Med. 2021, 10, 83. https://doi.org/10.3390/jcm10010083

AMA Style

Magnocavallo M, Bellasi A, Mariani MV, Fusaro M, Ravera M, Paoletti E, Di Iorio B, Barbera V, Della Rocca DG, Palumbo R, et al. Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy. Journal of Clinical Medicine. 2021; 10(1):83. https://doi.org/10.3390/jcm10010083

Chicago/Turabian Style

Magnocavallo, Michele, Antonio Bellasi, Marco Valerio Mariani, Maria Fusaro, Maura Ravera, Ernesto Paoletti, Biagio Di Iorio, Vincenzo Barbera, Domenico Giovanni Della Rocca, Roberto Palumbo, and et al. 2021. "Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy" Journal of Clinical Medicine 10, no. 1: 83. https://doi.org/10.3390/jcm10010083

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop